Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix®30 FlexPen™ in Type 2 Diabetic Patients Previously Treated in BIAsp-1236

This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.

Inclusion Criteria:

• Signed informed consent obtained before any trial-related activities
• Completed the trial BIAsp-1236

Exclusion Criteria:

• Planned changes in use of any prescription medication that may interfere with glucose regulation
• Known or suspected allergy to trial products or related products
• Women who are having the intention of becoming pregnant, or are judged not to be using adequate contraceptive measures
• Any other significant condition or concomitant disease or any condition that would interfere with participation as judged by the Investigator